“…Also, we agree with the authors [3] that the measurement of novel circulating biomarkers may offer the possibility to diagnose sarcopenia in those conditions, including ICU, where muscle strength cannot be easily assessed. For these reasons, Qaisar et al explored the association between c-terminal argin fragment 22 (CAF22) plasma levels (a product of neuromuscular junction degeneration) and sarcopenia in COVID-19 patients showing that, among the non-sarcopenic individuals, at baseline the group which developed sarcopenia presented with higher CAF22 levels than the remaining participants [3].…”